Doug Drysdale

From his beginnings at DuPont Merck to his current position as Cybin’s (NYSE: CYBN) CEO, Doug Drysdale has certainly had an eventful career. “I seem to be drawn to opportunities that are poised for growth, whether that is from being undermanaged, distressed or a startup situation,...

Media company Global Trac Solutions, Inc. (OTCP:PSYC) and authorities behind psychedelic news and information platform Psychedelic Spotlight, announced that Psychedelic Spotlight will host its first “CEO Roundtable” on Feb. 15. The event is scheduled to be streamed live on YouTube via...

Psychedelics company Cybin Inc. (NEO: CYBN) (AMEX: CYBN) announced that the U.S. Patent and Trademark Office has granted U.S. patent 11,242,318 to the company’s investigational deuterated dimethyltryptamine (“DMT”) compound CYB004. The allowed claims include a range of...

On Tuesday, three public companies in the psychedelics/biotech space announced significant milestones in their drug development pipelines. Field Trip Receives Notice Of Patent Allowance For Proprietary Psychedelic Molecule Field Trip Health (NASDAQ: FTRP) received a notice of allowance for a US...

Cybin Inc (NASDAQ: CYBN) shares are trading higher after the company announced an Institutional Review Board granted approval for a Cybin-sponsored feasibility study using Kernel Flow technology to measure psychedelic effects on the brain. “By leveraging the Kernel Flow technology, we may...

Toronto-based, Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics,” reported its unaudited financial results on Monday for the second quarter ended September 30, 2021. Second-Quarter Financial Highlights Cash...

Cybin Inc (NYSE: CYBN), a Toronto-based biotechnology company focused on utilizing psychedelic drugs as an alternative to traditional psychiatric drugs, announced positive pre-clinical data, indicating that its drug, CYB003 showed strong signs of cognitive improvement in patients with Major...

Detroit Decriminalizes Psychedelics Detroit is the latest to join the growing list of U.S. cities that have decriminalized psychedelic substances. The measure under which the Motor City will “decriminalize to the fullest extent permitted under Michigan law the personal possession and...

Cybin (NYSE: CYBN), a biotech company in the psychedelics space, began listing its stock on the New York Stock Exchange on Thursday. The company is the first in the sector to enter the NYSE, following a trend of five psychedelics companies to debut on the Nasdaq since the beginning of the year....

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced on Tuesday it has received initial clearance to begin a Phase IIa clinical trial on psilocybin for patients suffering from major depressive disorders (MDD). The head-...

Boston Suburbs Look To Decriminalize Natural Psychedelics Two Boston suburbs are the latest U.S. jurisdictions to eliminate penalties on the possession and cultivation of entheogenic plants and fungi. That includes psilocybin mushrooms, ayahuasca, the peyote cacti and the iboga...

Canada Allows Professionals In Training To Use Psilocybin The Canadian Health Minister Patty Hajdu has allowed 17 healthcare professionals to possess and use psilocybin to conduct professional training in psilocybin-assisted therapy. The decision, announced Tuesday, marks the latest step in Canada...

Compass Pathways Files for an IPO at NASDAQ UK-based Compass Pathways wants to become the first psychedelics company to list on a major U.S. stock exchange. The psilocybin research company intends to make its initial public offering (IPO) through NASDAQ under the ticker symbol...